Dynasil Corporation of America (DYSL) 10-Q 12 May 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Mar. 31, 2014	5-May-14
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'DYSL	'
Entity Common Stock, Shares Outstanding	'	15,543,268
Entity Registrant Name	'DYNASIL CORP OF AMERICA	'
Entity Central Index Key	'0000030831	'
Current Fiscal Year End Date	'--09-30	'
Entity Filer Category	'Smaller Reporting Company	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Sep. 30, 2013
Current Assets	'	'
Cash and cash equivalents	$3,465,644	$2,436,828
Accounts receivable, net of allowances of $318,792 and $184,775 at March 31, 2014 and September 30, 2013, respectively	2,781,759	3,657,320
Costs in excess of billings and unbilled receivables	1,917,012	1,537,318
Inventories, net of reserves	2,979,550	3,140,244
Prepaid expenses and other current assets	1,387,620	1,291,942
Total current assets	12,531,585	12,063,652
Property, Plant and Equipment, net	4,670,360	4,773,779
Other Assets	'	'
Intangibles, net	1,321,561	3,484,583
Goodwill	6,272,228	6,240,983
Deferred financing costs, net	37,739	114,229
Total other assets	7,631,528	9,839,795
Total Assets	24,833,473	26,677,226
Current Liabilities	'	'
Current portion of long-term debt	1,976,769	9,819,048
Capital lease obligations, current	128,979	124,383
Accounts payable	2,283,275	2,056,262
Deferred revenue	193,890	515,790
Accrued expenses and other liabilities	3,482,572	2,846,850
Total current liabilities	8,065,485	15,362,333
Long-term Liabilities	'	'
Long-term debt, net of current portion	3,127,795	0
Capital lease obligations, net of current portion	163,116	232,173
Convertible notes	383,084	0
Pension liability	249,966	249,966
Deferred tax liability	179,927	186,866
Total long-term liabilities	4,103,888	669,005
Stockholders' Equity	'	'
Common Stock, $0.0005 par value, 40,000,000 shares authorized, 16,318,753 and 16,224,402 shares issued, 15,508,593 and 15,414,242 shares outstanding at March 31, 2014 and September 30, 2013, respectively.	8,159	8,112
Additional paid in capital	17,722,381	17,476,003
Accumulated other comprehensive income	225,694	152,685
Accumulated deficit	-4,275,305	-6,004,570
Less 810,160 shares of treasury stock - at cost	-986,342	-986,342
Total Dynasil stockholders' equity	12,694,587	10,645,888
Noncontrolling interest	-30,487	0
Total stockholders' equity	12,664,100	10,645,888
Total Liabilities and Stockholders' Equity	$24,833,473	$26,677,226

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Mar. 31, 2014	Sep. 30, 2013
Allowance for doubtful accounts (in dollars)	$318,792	$184,775
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	16,318,753	16,224,402
Common stock, shares outstanding	15,508,593	15,414,242
Treasury stock, shares	810,160	810,160

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Net revenue	$10,406,458	$10,484,530	$21,117,986	$21,037,805
Cost of revenue	6,047,571	5,843,017	12,308,571	11,890,038
Gross profit	4,358,887	4,641,513	8,809,415	9,147,767
Operating expenses:	'	'	'	'
Sales and marketing	312,729	486,544	709,534	966,422
Research and development	378,379	573,229	724,577	1,210,358
General and administrative	3,200,552	4,066,682	6,480,546	7,647,216
Impairment of goodwill and long-lived assets	0	6,763,072	0	6,763,072
Total operating expenses	3,891,660	11,889,527	7,914,657	16,587,068
Gain on sale of assets	0	0	-1,186,686	0
Income (loss) from operations	467,227	-7,248,014	2,081,444	-7,439,301
Interest expense, net	209,330	177,159	422,107	363,916
Income (loss) before taxes	257,897	-7,425,173	1,659,337	-7,803,217
Income tax (credit) provision	4,602	-183,443	-39,441	-182,145
Net income (loss)	253,295	-7,241,730	1,698,778	-7,621,072
Less: Net loss attributable to noncontrolling interest	-18,300	0	-30,487	0
Net income (loss) attributable to common stockholders	271,595	-7,241,730	1,729,265	-7,621,072
Net income (loss)	253,295	-7,241,730	1,698,778	-7,621,072
Other comprehensive income (loss):	'	'	'	'
Foreign currency translation	36,845	-275,360	73,009	-245,621
Total comprehensive income (loss)	$290,140	($7,517,090)	$1,771,787	($7,866,693)
Basic net income (loss) per common share (in dollars per share)	$0.02	($0.49)	$0.11	($0.52)
Diluted net income (loss) per common share (in dollars per share)	$0.02	($0.49)	$0.11	($0.52)
Weighted average shares outstanding	'	'	'	'
Basic (in shares)	15,102,023	14,770,943	15,061,890	14,721,733
Diluted (in shares)	15,285,232	14,770,943	15,216,915	14,721,733

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
Balance at Sep. 30, 2013	$10,645,888	$8,112	$17,476,003	$152,685	($6,004,570)	($986,342)	$0
Balance (in shares) at Sep. 30, 2013	'	16,224,402	'	'	'	810,160	'
Issuance of shares of common stock under employee stock purchase plan	8,471	3	8,468	0	0	0	0
Issuance of shares of common stock under employee stock purchase plan (in shares)	'	6,138	'	'	'	0	'
Stock-based compensation costs	237,954	44	237,910	0	0	0	0
Stock-based compensation costs (in shares)	'	88,213	'	'	'	0	'
Foreign currency translation adjustment	73,009	0	0	73,009	0	0	0
Net income (loss)	1,698,778	0	0	0	1,729,265	0	-30,487
Balance at Mar. 31, 2014	$12,664,100	$8,159	$17,722,381	$225,694	($4,275,305)	($986,342)	($30,487)
Balance (in shares) at Mar. 31, 2014	'	16,318,753	'	'	'	810,160	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net income (loss)	$1,698,778	($7,621,072)
Adjustments to reconcile net income (loss) to net cash:	'	'
Stock compensation expense	239,225	210,128
Foreign exchange loss	14,029	-31,275
Gain on sale of assets	-1,186,686	-87,803
Depreciation and amortization	534,773	870,175
Other	73,320	-148,955
Impairment of goodwill and long-lived assets	0	6,763,072
Other changes in assets and libilities:	'	'
Accounts receivable, net	447,291	1,102,777
Inventories	-531,817	-359,106
Costs in excess of billings and unbilled receivables	-379,694	-19,387
Prepaid expenses and other assets	-99,005	-84,600
Accounts payable	230,348	112,126
Accrued expenses and other liabilities	883,309	-963,447
Deferred revenue	-319,565	38,178
Net cash provided by (used in) operating activities	1,604,306	-219,189
Cash flows from investing activities:	'	'
Proceeds from sale of assets	4,357,219	80,252
Purchases of property, plant and equipment	-539,476	-215,679
Net cash provided by (used in) investing activities	3,817,743	-135,427
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock	7,200	11,688
Net proceeds from issuance of convertible notes	383,084	0
Principal payments on capital leases	-64,461	-21,056
Proceeds from long-term debt	141,348	0
Payments on long-term debt	-4,855,832	-936,873
Net cash used in financing activities	-4,388,661	-946,241
Effect of exchange rates on cash and cash equivalents	-4,572	18,878
Net increase (decrease) in cash and cash equivalents	1,028,816	-1,281,979
Cash and cash equivalents, beginning	2,436,828	3,414,880
Cash and cash equivalents, ending	3,465,644	2,132,901
Non cash activities:	'	'
Assets purchased under capital leases	$0	$386,680

Basis_of_Presentation_and_Abil

Basis of Presentation and Ability to Continue as a Going Concern	6 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	Note 1 - Basis of Presentation and Ability to Continue as a Going Concern
	The accompanying consolidated balance sheet as of March 31, 2014, the consolidated statements of operations and comprehensive income (loss) for the three months and six months ended March 31, 2014 and 2013, changes in stockholders’ equity for the six months ended March 31, 2014 and cash flows for the six months ended March 31, 2014 and 2013 of Dynasil Corporation of America and subsidiaries (the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year.
	The preparation of unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company's annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's September 30, 2013 Annual Report on Form 10-K previously filed by the Company with the Securities and Exchange Commission.
	The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company incurred substantial losses from operations for the fiscal years ended September 30, 2013 and 2012 and failed to comply with the financial covenants set forth in the terms of its outstanding loan agreements for the fiscal year ended September 30, 2012 and each of the quarters during the fiscal year ended September 30, 2013. These covenants required the Company to maintain specified ratios of earnings before interest, taxes, depreciation and amortization (EBITDA) to fixed charges and to total/senior debt.
	The Company returned to profitability for the three month period ended December 31, 2013 and regained compliance with the financial covenants described above. However Santander Bank, N.A. (“Santander”), the Company’s senior lender, continued to require that it not pay interest due monthly to our subordinated lender, Massachusetts Capital Resource Company, constituting a separate event of default. In addition, Santander advised the Company that it was unwilling to negotiate regarding waivers for our past quarterly covenant violations after we reported that it had regained compliance for the three months ended December 31, 2013.
	On May 1, 2014, the Company entered into a three year revolving line of credit arrangement with a new bank for up to $4 million with the amount available for advances determined monthly based on eligible billed and unbilled accounts receivable and inventory. The line of credit is secured by substantially all the Company’s assets. Upon the closing of the loan, the Company repaid the approximately $1.8 million owed the senior lender and the $600,000 of accrued interest due the subordinated lender through April 30, 2014. The subordinated lender also issued a waiver to the Company for prior covenant violations.
	As a result, the Company is no longer in default of any of its loan obligations and has reclassified the subordinated debt to a long term liability based on its terms.
	The Company considers events or transactions that have occurred after the unaudited consolidated balance sheet date of March 31, 2014, but prior to the filing of the unaudited consolidated financial statements with the SEC on this Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.

Businesses_Sold

Businesses Sold	6 Months Ended
	Mar. 31, 2014
Businesses Sold [Abstract]	'
Businesses Sold [Text Block]	'
	Note 2 – Businesses Sold
	In the first quarter of 2014, the Company sold its lead paint detection and medical instruments businesses which comprised substantially all operating assets of its Instruments segment.
	On November 7, 2013, the Company sold its Lead Paint detector business to Protec Instrument Corporation (“Protec”), a wholly owned subsidiary of Laboratoires Protec S.A., a French corporation and former European distributor of the Company’s lead paint detector products. The sales price totaled approximately $1.2 million, including the assumption of certain liabilities by Protec. The transaction also resulted in payment to the Company of approximately $500,000 in satisfaction of outstanding accounts receivable. Concurrently with the sale, the Company and Protec entered into a transition services agreement pursuant to which the Company will provide certain transitional services to Protec for up to five months after closing. The Company used $1.175 million of the proceeds from the sale to reduce its indebtedness to Santander Bank, N.A.
	On December 23, 2013, the Company sold its Gamma Medical Probe business to Dilon Technologies, Inc., a Delaware corporation (“Dilon”), for $3.5 million, the assumption of certain liabilities of the Company, and a possible contingent payment. The Agreement also provided for $250,000 of the proceeds to be deposited in escrow for a year, which amount is included in accounts receivable in the Consolidated Balance Sheet. The Asset Purchase Agreement (“Agreement”) contains customary representations, warranties, covenants and indemnification provisions. Concurrently with the sale, the Company and Dilon entered into a transition services agreement pursuant to which the Company will provide certain transitional services to Dilon for up to five months after closing. The Company used $2.75 million of the proceeds from the sale to reduce its indebtedness to Santander Bank, N.A.
	In connection with the sales of the businesses discussed above, the Company recorded a gain of $1.2 million which is included in Income from Operations in the three months ended December 31, 2013. The businesses sold constituted substantially all of Instruments segment but did not constitute a component of the business, and therefore did not qualify to be reported as discontinued operations. The assets held for sale at September 30, 2013 included fixed assets, inventory, and intangible customer assets totaling $2.9 million offset by customer deposits of approximately $100,000.

Formation_of컞Technologie

Formation of Xcede Technologies, Inc. Joint Venture	6 Months Ended
	Mar. 31, 2014
Equity Method Investments and Joint Ventures [Abstract]	'
Equity Method Investments and Joint Ventures Disclosure [Text Block]	'
	Note 3 – Formation of Xcede Technologies, Inc. Joint Venture
	On or about October 1, 2013, the Company formed Xcede Technologies, Inc. (“Xcede”), a joint venture with Mayo Clinic, in order to spin out and separately fund the development of its tissue sealant technology which formerly comprised the majority of its Biomedical segment. Xcede had received a total of approximately $400,000 in funding through March 31, 2014 in the form of Convertible Notes from outside investors including certain directors of the Company. The notes accrue interest at 5%. Upon the closing of a capital stock financing, the outstanding principal amount of the notes plus all accrued but unpaid interest on the notes will be converted into shares of the same capital stock sold in the capital stock financing at a 20% discount to the price per share of that capital stock financing. Alternatively, at any time prior to a capital stock financing the note holders can convert at their option into common stock based on a $5 million valuation.
	Xcede is continuing its fund raising efforts as it will require additional funding in connection with human trials expected to commence in the fourth quarter of 2014. Subsequent to March 31, 2014, Xcede has raised approximately $250,000 of additional funds.
	Xcede’s common stock is 90% owned by Dynasil Biomedical and, as a result, is included in the Company’s consolidated balance sheet, results of operations and cash flows. Dynasil holds a majority of the seats on Xcede’s board of directors.

Inventories

Inventories	6 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 4 - Inventories
	Inventories, net of reserves, consists of the following:
		March 31,		September 30,
		2014		2013
	Raw Materials	$	1,741,628	$	2,132,962
	Work-in-Process		975,194		703,873
	Finished Goods		262,728		303,409
		$	2,979,550	$	3,140,244

Intangible_Assets

Intangible Assets	6 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 5 – Intangible Assets
	Intangible assets at March 31, 2014 and September 30, 2013 consist of the following:
		Useful		Gross		Accumulated
	March 31, 2014	Life (years)		Amount		Amortization		Net
	Acquired Customer Base		5 to 15	$	888,318	$	375,380	$	512,938
	Know How		15		512,000		196,349		315,651
	Trade Names		Indefinite		344,639		-		344,639
	Biomedical Technologies		5		260,000		111,667		148,333
				$	2,004,957	$	683,396	$	1,321,561
		Useful		Gross		Accumulated
	September 30, 2013	Life (years)		Amount		Amortization		Net
	Acquired Customer Base		5 to 15	$	5,145,638	$	2,645,715	$	2,499,923
	Know How		15		512,000		179,283		332,717
	Trade Names		15 or Indefinite		547,802		75,856		471,946
	Biomedical Technologies		5		300,000		120,003		179,997
				$	6,505,440	$	3,020,857	$	3,484,583
	Amortization expense for the three months ended March 31, 2014 and 2013 was $43,667 and $143,506, respectively. Amortization expense for the six months ended March 31, 2014 and 2013 was $88,555 and $324,774, respectively. Estimated amortization expense for each of the next five fiscal years is as follows:
		2014 (6 months)		2015		2016		2017		2018		Thereafter		Total
	Acquired Customer Base	$	39,976	$	79,952	$	79,952	$	79,952	$	79,952	$	153,154	$	512,938
	Know How		17,067		34,133		34,133		34,133		34,133		162,052		315,651
	Biomedical Technologies		30,000		60,000		58,333		-		-		-		148,333
		$	87,043	$	174,085	$	172,418	$	114,085	$	114,085	$	315,206	$	976,922

Goodwill

Goodwill	6 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill Disclosure [Text Block]	'
	Note 6 – Goodwill
	Goodwill is subject to an annual impairment test. The Company considers many factors which may indicate the requirement to perform additional, interim impairment tests. These include:
		·	A significant adverse long term outlook for any of its industries;
		·	An adverse finding or rejection from a regulatory body involved in new product regulatory approvals;
		·	Failure of an anticipated commercialization of a product or product line;
		·	Unanticipated competition or the introduction of a disruptive technology;
		·	The testing for recoverability under the Impairment or Disposal of Long-Lived Assets Subsections of Subtopic 360-10 of a significant asset group within a reporting unit;
		·	A loss of key personnel; and
		·	An expectation that a reporting unit carrying goodwill, or a significant portion of a reporting unit, will be sold or otherwise disposed of.
	There were no changes, aside from foreign exchange rate fluctuations, in the carrying value of goodwill during the three and six months ended March 31, 2014.

Earnings_Loss_Per_Common_Share

Earnings (Loss) Per Common Share	6 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 7 – Earnings (Loss) Per Common Share
	Basic earnings (loss) per common share is computed by dividing the net income applicable or loss attributable to common shares by the weighted average number of common shares. Diluted earnings per common share adjusts basic earnings per share for the effects of common stock options, common stock warrants, convertible preferred stock and other potential dilutive common shares outstanding during the periods.
	For purposes of computing diluted earnings per share for the three and six months ended March 31, 2014 and 2013, no common stock options were included in the calculation of dilutive shares as all of the 630,532 and 710,532 common stock options outstanding, respectively, had exercise prices above the current quarterly average market price per share and their inclusion is anti-dilutive. Additionally, for the three and six months ended March 31, 2013, no common share equivalents related to stock options or unvested restricted stock were included in the calculation of dilutive shares, since there was a loss from continuing operations and the inclusion of common share equivalents would have been anti-dilutive.
	The computation of the weighted shares outstanding for the three months ended March 31 is as follows:
		March 31, 2014		March 31, 2013
	Weighted average shares outstanding
	Basic		15,102,023		14,770,943
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		183,209		-
	Dilutive Average Shares Outstanding		15,285,232		14,770,943
	The computation of the weighted shares outstanding for the six months ended March 31 is as follows:
		March 31, 2014		March 31, 2013
	Weighted average shares outstanding
	Basic		15,061,890		14,721,733
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		155,025		-
	Dilutive Average Shares Outstanding		15,216,915		14,721,733

Stock_Based_Compensation

Stock Based Compensation	6 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 8 - Stock Based Compensation
	The fair value of the stock options granted is estimated at the date of grant using the Black-Scholes option pricing model.
	A summary of stock option activity for the six months ended March 31, 2014 and 2013 is presented below:
		Options		Weighted Average		Weighted Average
		Outstanding		Exercise Price per		Remain Contractual
				Share		Term (in Years)
	Balance at September 30, 2013		630,532	$	3.33		1.06
	Outstanding and exercisable at September 30, 2013		630,532	$	3.33		1.06
	Granted		-		-
	Exercised		-		-
	Cancelled		-		-
	Balance at March 31, 2014		630,532	$	3.33		0.56
	Outstanding and exercisable at March 31, 2014		630,532	$	3.33		0.56
		Options		Weighted Average		Weighted Average
		Outstanding		Exercise Price per		Remain Contractual
				Share		Term (in Years)
	Balance at September 30, 2012		794,483	$	3.34		1.75
	Outstanding and exercisable at September 30, 2012		794,483	$	3.34		1.75
	Granted		-		-
	Exercised		-		-
	Cancelled		-83,951	$	3.69
	Balance at March 31, 2013		710,532	$	3.3		1.41
	Outstanding and exercisable at March 31, 2013		710,532	$	3.3		1.41
	A summary of restricted stock activity for the six months ended March 31, 2014 and 2013 is presented below:
	Restricted Stock Activity for the Six	Shares		Weighted-Average
	Months ended March 31, 2014			Grant-Date Fair Value
	Nonvested at September 30, 2013		423,168	$	0.74
	Granted		-	$	-
	Vested		-50,000	$	1.05
	Cancelled		-	$	-
	Nonvested at March 31, 2014		373,168	$	0.7
	Restricted Stock Activity for the Six	Shares		Weighted-Average
	Months ended March 31, 2013			Grant-Date Fair Value
	Nonvested at September 30, 2012		127,834	$	1.92
	Granted		104,000	$	1.03
	Vested		-53,000	$	1.21
	Cancelled		-20,000	$	4.02
	Nonvested at March 31, 2013		158,834	$	1.31
	Stock Compensation Expense for the six months ended March 31, 2014 and 2013 is as follows:
		Three Months Ended		Three Months Ended
	Stock Compensation Expense	31-Mar-14		31-Mar-13
	Stock Grants	$	50,627	$	80,091
	Restricted Stock Grants		68,351		53,076
	Option Grants		-		2,454
	Employee Stock Purchase Plan		601		991
	Total	$	119,579	$	136,612
		Six Months Ended		Six Months Ended
	Stock Compensation Expense	March 31, 2014		March 31, 2013
	Stock Grants	$	101,253	$	132,552
	Restricted Stock Grants		136,702		65,694
	Option Grants		-		9,813
	Employee Stock Purchase Plan		1,270		2,069
	Total	$	239,225	$	210,128
	At March 31, 2014 there was approximately $103,000 in unrecognized stock compensation cost, which is expected to be recognized over a weighted average period of approximately five months.

Segment_Customer_and_Geographi

Segment, Customer and Geographical Reporting	6 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 9 – Segment, Customer and Geographical Reporting
	Segment Financial Information
	Dynasil’s business is comprised of four segments: contract research (“Contract Research”), optics (“Optics”), instruments (“Instruments”) and biomedical (“Biomedical”). Within these segments, there is a segregation of reportable units based upon the organizational structure used to evaluate performance and make decisions on resource allocation, as well as availability and materiality of separate financial results consistent with that structure. The Contract Research segment is one of the largest small business participants in U.S. government-funded research. The Optics segment manufactures optical materials, components and coatings. The Instruments segment manufactures specialized instruments used in various applications in the medical, industrial, and homeland security/defense sectors. The Biomedical segment, through Xcede Technologies, Inc., a majority owned, joint venture (“Xcede”), is focused on developing a tissue sealant technology for a wide spectrum of applications though no assurance can be given that this technology will become successfully commercialized.
	As discussed in Note 2, substantially all the operating assets of the Instruments segment were sold in the three months ended December 31, 2013.
	The Company’s segment information for the three months ended March 31, 2014 and 2013 is summarized below:
	Results of Operations for the Three Months Ended March 31,
	2014
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	5,614,060	$	4,788,669		$	-		$	3,729		$	10,406,458
	Gross Profit		2,441,719		1,919,261			-5,822			3,729			4,358,887
	Impairment of goodwill		-		-			-			-			-
	Operating Income (Loss)		241,938		522,112			-75,585			-221,238			467,227
	Depreciation and Amortization		69,949		183,499			-			15,000			268,448
	Capital expenditures		12,028		396,530			-			-			408,558
	Intangibles, Net		315,651		857,579			-			148,331			1,321,561
	Goodwill		4,938,625		1,333,603			-			-			6,272,228
	Total Assets	$	10,230,207	$	13,815,832		$	455,096		$	332,338		$	24,833,473
	Results of Operations for the Three Months Ended March 31,
	2013
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	5,487,850	$	3,931,766		$	1,014,320		$	50,594		$	10,484,530
	Gross Profit		2,647,870		1,481,948			461,101			50,594			4,641,513
	Impairment of goodwill		-		-			6,763,072			-			6,763,072
	Operating Income (Loss)		232,015		2,336			-7,270,801			-211,564			-7,248,014
	Depreciation and Amortization		79,637		184,696			164,384			15,000			443,717
	Capital expenditures		-187,425		87,536			-			-			-99,889
	Intangibles, Net		349,786		866,488			2,349,767			209,997			3,776,038
	Goodwill		4,938,625		1,197,017			-			-			6,135,642
	Total Assets	$	13,332,151	$	9,748,703		$	4,862,956		$	334,658		$	28,278,468
	The Company’s segment information for the six months ended March 31, 2014 and 2013 is summarized below:
	Results of Operations for the Six Months Ended March 31,
	2014
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	11,454,502	$	8,887,177		$	772,578		$	3,729		$	21,117,986
	Gross Profit		4,971,257		3,516,521			317,908			3,729			8,809,415
	Impairment of goodwill		-		-			-			-			-
	Operating Income (Loss)		590,332		920,544			966,178			-395,610			2,081,444
	Depreciation and Amortization		139,496		361,607			2,003			31,667			534,773
	Capital expenditures		12,028		527,448			-			-			539,476
	Intangibles, Net		315,651		857,579			-			148,331			1,321,561
	Goodwill		4,938,625		1,333,603			-			-			6,272,228
	Total Assets	$	10,230,207	$	13,815,832		$	455,096		$	332,338		$	24,833,473
	Results of Operations for the Six Months Ended March 31,
	2013
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	10,398,690	$	8,183,706		$	2,298,358		$	157,051		$	21,037,805
	Gross Profit		4,861,923		3,061,891			1,066,902			157,051			9,147,767
	Impairment of goodwill		-		-			6,763,072			-			6,763,072
	Operating Income (Loss)		231,409		388,012			-7,726,495			-332,227			-7,439,301
	Depreciation and Amortization		142,419		370,324			327,432			30,000			870,175
	Capital expenditures		-1,095		209,682			7,092			-			215,679
	Intangibles, Net		349,786		866,488			2,349,767			209,997			3,776,038
	Goodwill		4,938,625		1,197,017			-			-			6,135,642
	Total Assets	$	13,332,151	$	9,748,703		$	4,862,956		$	334,658		$	28,278,468
	Customer Financial Information
	For the three and six months ended March 31, 2014 and 2013, the top three customers for the Contract Research segment were various agencies of the U.S. Government. For the three months ended March 31, 2014 and 2013, these customers made up 69% and 64%, respectively, of Contract Research revenue. For the six months ended March 31, 2014 and 2013, these customers made up 67% and 63%, respectively, of Contract Research revenue.
	For the three and six months ended March 31, 2014 and 2013, there was no customer in the Optics segment whose revenue represented more than 10% of the total segment revenue.
	For the three months ended March 31, 2014, there was no revenue in the Instruments segment. For the three months ended March 31, 2013, the top three customers for the Instruments segment made up 30% of Instruments revenue. For the six months ended March 31, 2014 and 2013, the top three customers for the Instruments segment made up 24% and 32%, respectively, of Instruments revenue.
	For the both three and six months ended March 31, 2014 and 2013, the Biomedical segment had one customer whose revenue represented 100% of the total segment revenue.
Geographic Financial Information
Revenue by geographic location in total and as a percentage of total revenue, for the three months ended March 31, 2014 and 2013 are as follows:
	Three Months Ended						Three Months Ended
	March 31, 2014						March 31, 2013
Geographic Location	Revenue		% of Total				Revenue			% of Total
United States	$	8,621,552		83	%		$	8,572,033			82	%
Europe		844,963		8	%			847,662			8	%
Other		939,943		9	%			1,064,835			10	%
	$	10,406,458		100	%		$	10,484,530			100	%
Revenue by geographic location in total and as a percentage of total revenue, for the six months ended March 31, 2014 and 2013 are as follows:
	Six Months Ended						Six Months Ended
	March 31, 2014						March 31, 2013
Geographic Location	Revenue		% of Total				Revenue			% of Total
United States	$	17,529,282		83	%		$	17,066,521			81	%
Europe		1,674,400		8	%			1,736,003			8	%
Other		1,914,304		9	%			2,235,281			11	%
	$	21,117,986		100	%		$	21,037,805			100	%

Income_Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 10 - Income Taxes
	Dynasil Corporation of America and its wholly-owned U.S. subsidiaries file a consolidated federal income tax return and various state returns. The Company’s U.K. subsidiary files tax returns in the U.K.
	The Company uses the asset and liability approach to account for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carry forwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates, and tax laws, in the respective tax jurisdiction then in effect.
	In assessing the ability to realize the net deferred tax assets, management considers various factors including taxable income in carryback years, future reversals of existing taxable temporary differences, tax planning strategies and projections of future taxable income, to determine whether it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Based upon the Company’s recent losses and uncertainty of future profits, the Company has determined that the uncertainty regarding the realization of these assets is sufficient to warrant the need for a full valuation allowance against its U.S. net deferred tax assets.
	The Company applies the authoritative provisions related to accounting for uncertainty in income taxes. As required by these provisions, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being reached upon ultimate settlement with the relevant tax authority. As of March 31, 2014 and September 30, 2013, the Company has no unrecorded liabilities for uncertain tax positions. Interest and penalty charges, if any, related to uncertain tax positions would be classified as income tax expense in the accompanying consolidated statement of operations. As of March 31, 2014 and September 30, 2013, the Company had no accrued interest or penalties related to uncertain tax positions. The Company currently has no federal or state tax examinations in progress.
	The effective tax rates were 1.8% and (2.4%) for the three and six months ended March 31, 2014, respectively, and 2.5% and 2.3% for the three and six months ended March 31, 2013, respectively. The rates differ from the U.S. federal statutory income tax rate of 34% primarily due to a full valuation allowance against the Company’s U.S. deferred tax asset.
	The Company files its tax returns as prescribed by the tax laws of the jurisdictions in which it operates. The Company’s tax filings for federal and state jurisdictions for the tax years beginning with 2010 are still subject to examination.

Subsequent_Events

Subsequent Events	6 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 11 – Subsequent Events
	The Company has evaluated subsequent events through the date that the financial statements were released.
	On May 1, 2014, the Company entered into an agreement with Middlesex Savings Bank to establish a revolving line of credit of up to $4 million, subject to availability restrictions described below. Upon the closing of the loan, the Company repaid in full the approximately $1.8 million owed Santander Bank and the $600,000 of accrued interest due, as of April 30, 2014, to Massachusetts Capital Resource Company, its subordinated lender. As a result, as of May 1, 2014, the Company has total indebtedness outstanding consisting of $2.4 million newly drawn senior debt owed to Middlesex Savings Bank and approximately $3.0 million of existing subordinated debt owed to Massachusetts Capital Resource Company due July 2017.
	The Bank Loan Agreement provides that the revolving line of credit expires May 2017 and is secured by substantially all the Company's assets. Borrowing availability under the revolving line of credit is determined monthly based on eligible billed and unbilled accounts receivable and inventory. The Company is required to maintain compliance with a debt to service coverage ratio. The interest rate on the loan is equal to the Prime Rate, but in no event less than 3.25%.

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories, net of reserves, consists of the following:
		March 31,		September 30,
		2014		2013
	Raw Materials	$	1,741,628	$	2,132,962
	Work-in-Process		975,194		703,873
	Finished Goods		262,728		303,409
		$	2,979,550	$	3,140,244

Intangible_Assets_Tables

Intangible Assets (Tables)	6 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Intangible assets at March 31, 2014 and September 30, 2013 consist of the following:
		Useful		Gross		Accumulated
	March 31, 2014	Life (years)		Amount		Amortization		Net
	Acquired Customer Base		5 to 15	$	888,318	$	375,380	$	512,938
	Know How		15		512,000		196,349		315,651
	Trade Names		Indefinite		344,639		-		344,639
	Biomedical Technologies		5		260,000		111,667		148,333
				$	2,004,957	$	683,396	$	1,321,561
		Useful		Gross		Accumulated
	September 30, 2013	Life (years)		Amount		Amortization		Net
	Acquired Customer Base		5 to 15	$	5,145,638	$	2,645,715	$	2,499,923
	Know How		15		512,000		179,283		332,717
	Trade Names		15 or Indefinite		547,802		75,856		471,946
	Biomedical Technologies		5		300,000		120,003		179,997
				$	6,505,440	$	3,020,857	$	3,484,583
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Amortization expense for the three months ended March 31, 2014 and 2013 was $43,667 and $143,506, respectively. Amortization expense for the six months ended March 31, 2014 and 2013 was $88,555 and $324,774, respectively. Estimated amortization expense for each of the next five fiscal years is as follows:
		2014 (6 months)		2015		2016		2017		2018		Thereafter		Total
	Acquired Customer Base	$	39,976	$	79,952	$	79,952	$	79,952	$	79,952	$	153,154	$	512,938
	Know How		17,067		34,133		34,133		34,133		34,133		162,052		315,651
	Biomedical Technologies		30,000		60,000		58,333		-		-		-		148,333
		$	87,043	$	174,085	$	172,418	$	114,085	$	114,085	$	315,206	$	976,922

Earnings_Loss_Per_Common_Share1

Earnings (Loss) Per Common Share (Tables)	6 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The computation of the weighted shares outstanding for the three months ended March 31 is as follows:
		March 31, 2014		March 31, 2013
	Weighted average shares outstanding
	Basic		15,102,023		14,770,943
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		183,209		-
	Dilutive Average Shares Outstanding		15,285,232		14,770,943
	The computation of the weighted shares outstanding for the six months ended March 31 is as follows:
		March 31, 2014		March 31, 2013
	Weighted average shares outstanding
	Basic		15,061,890		14,721,733
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		155,025		-
	Dilutive Average Shares Outstanding		15,216,915		14,721,733

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	6 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	A summary of stock option activity for the six months ended March 31, 2014 and 2013 is presented below:
		Options		Weighted Average		Weighted Average
		Outstanding		Exercise Price per		Remain Contractual
				Share		Term (in Years)
	Balance at September 30, 2013		630,532	$	3.33		1.06
	Outstanding and exercisable at September 30, 2013		630,532	$	3.33		1.06
	Granted		-		-
	Exercised		-		-
	Cancelled		-		-
	Balance at March 31, 2014		630,532	$	3.33		0.56
	Outstanding and exercisable at March 31, 2014		630,532	$	3.33		0.56
		Options		Weighted Average		Weighted Average
		Outstanding		Exercise Price per		Remain Contractual
				Share		Term (in Years)
	Balance at September 30, 2012		794,483	$	3.34		1.75
	Outstanding and exercisable at September 30, 2012		794,483	$	3.34		1.75
	Granted		-		-
	Exercised		-		-
	Cancelled		-83,951	$	3.69
	Balance at March 31, 2013		710,532	$	3.3		1.41
	Outstanding and exercisable at March 31, 2013		710,532	$	3.3		1.41
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
	A summary of restricted stock activity for the six months ended March 31, 2014 and 2013 is presented below:
	Restricted Stock Activity for the Six	Shares		Weighted-Average
	Months ended March 31, 2014			Grant-Date Fair Value
	Nonvested at September 30, 2013		423,168	$	0.74
	Granted		-	$	-
	Vested		-50,000	$	1.05
	Cancelled		-	$	-
	Nonvested at March 31, 2014		373,168	$	0.7
	Restricted Stock Activity for the Six	Shares		Weighted-Average
	Months ended March 31, 2013			Grant-Date Fair Value
	Nonvested at September 30, 2012		127,834	$	1.92
	Granted		104,000	$	1.03
	Vested		-53,000	$	1.21
	Cancelled		-20,000	$	4.02
	Nonvested at March 31, 2013		158,834	$	1.31
Schedule Of Stock Compensation Expense [Table Text Block]	'
	Stock Compensation Expense for the six months ended March 31, 2014 and 2013 is as follows:
		Three Months Ended		Three Months Ended
	Stock Compensation Expense	31-Mar-14		31-Mar-13
	Stock Grants	$	50,627	$	80,091
	Restricted Stock Grants		68,351		53,076
	Option Grants		-		2,454
	Employee Stock Purchase Plan		601		991
	Total	$	119,579	$	136,612
		Six Months Ended		Six Months Ended
	Stock Compensation Expense	March 31, 2014		March 31, 2013
	Stock Grants	$	101,253	$	132,552
	Restricted Stock Grants		136,702		65,694
	Option Grants		-		9,813
	Employee Stock Purchase Plan		1,270		2,069
	Total	$	239,225	$	210,128

Segment_Customer_and_Geographi1

Segment, Customer and Geographical Reporting (Tables)	6 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The Company’s segment information for the three months ended March 31, 2014 and 2013 is summarized below:
	Results of Operations for the Three Months Ended March 31,
	2014
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	5,614,060	$	4,788,669		$	-		$	3,729		$	10,406,458
	Gross Profit		2,441,719		1,919,261			-5,822			3,729			4,358,887
	Impairment of goodwill		-		-			-			-			-
	Operating Income (Loss)		241,938		522,112			-75,585			-221,238			467,227
	Depreciation and Amortization		69,949		183,499			-			15,000			268,448
	Capital expenditures		12,028		396,530			-			-			408,558
	Intangibles, Net		315,651		857,579			-			148,331			1,321,561
	Goodwill		4,938,625		1,333,603			-			-			6,272,228
	Total Assets	$	10,230,207	$	13,815,832		$	455,096		$	332,338		$	24,833,473
	Results of Operations for the Three Months Ended March 31,
	2013
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	5,487,850	$	3,931,766		$	1,014,320		$	50,594		$	10,484,530
	Gross Profit		2,647,870		1,481,948			461,101			50,594			4,641,513
	Impairment of goodwill		-		-			6,763,072			-			6,763,072
	Operating Income (Loss)		232,015		2,336			-7,270,801			-211,564			-7,248,014
	Depreciation and Amortization		79,637		184,696			164,384			15,000			443,717
	Capital expenditures		-187,425		87,536			-			-			-99,889
	Intangibles, Net		349,786		866,488			2,349,767			209,997			3,776,038
	Goodwill		4,938,625		1,197,017			-			-			6,135,642
	Total Assets	$	13,332,151	$	9,748,703		$	4,862,956		$	334,658		$	28,278,468
	The Company’s segment information for the six months ended March 31, 2014 and 2013 is summarized below:
	Results of Operations for the Six Months Ended March 31,
	2014
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	11,454,502	$	8,887,177		$	772,578		$	3,729		$	21,117,986
	Gross Profit		4,971,257		3,516,521			317,908			3,729			8,809,415
	Impairment of goodwill		-		-			-			-			-
	Operating Income (Loss)		590,332		920,544			966,178			-395,610			2,081,444
	Depreciation and Amortization		139,496		361,607			2,003			31,667			534,773
	Capital expenditures		12,028		527,448			-			-			539,476
	Intangibles, Net		315,651		857,579			-			148,331			1,321,561
	Goodwill		4,938,625		1,333,603			-			-			6,272,228
	Total Assets	$	10,230,207	$	13,815,832		$	455,096		$	332,338		$	24,833,473
	Results of Operations for the Six Months Ended March 31,
	2013
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	10,398,690	$	8,183,706		$	2,298,358		$	157,051		$	21,037,805
	Gross Profit		4,861,923		3,061,891			1,066,902			157,051			9,147,767
	Impairment of goodwill		-		-			6,763,072			-			6,763,072
	Operating Income (Loss)		231,409		388,012			-7,726,495			-332,227			-7,439,301
	Depreciation and Amortization		142,419		370,324			327,432			30,000			870,175
	Capital expenditures		-1,095		209,682			7,092			-			215,679
	Intangibles, Net		349,786		866,488			2,349,767			209,997			3,776,038
	Goodwill		4,938,625		1,197,017			-			-			6,135,642
	Total Assets	$	13,332,151	$	9,748,703		$	4,862,956		$	334,658		$	28,278,468
Schedule Of Segment Revenue By Geographical Location [Table Text Block]	'
	Revenue by geographic location in total and as a percentage of total revenue, for the three months ended March 31, 2014 and 2013 are as follows:
		Three Months Ended						Three Months Ended
		March 31, 2014						March 31, 2013
	Geographic Location	Revenue		% of Total				Revenue			% of Total
	United States	$	8,621,552		83	%		$	8,572,033			82	%
	Europe		844,963		8	%			847,662			8	%
	Other		939,943		9	%			1,064,835			10	%
		$	10,406,458		100	%		$	10,484,530			100	%
	Revenue by geographic location in total and as a percentage of total revenue, for the six months ended March 31, 2014 and 2013 are as follows:
		Six Months Ended						Six Months Ended
		March 31, 2014						March 31, 2013
	Geographic Location	Revenue		% of Total				Revenue			% of Total
	United States	$	17,529,282		83	%		$	17,066,521			81	%
	Europe		1,674,400		8	%			1,736,003			8	%
	Other		1,914,304		9	%			2,235,281			11	%
		$	21,117,986		100	%		$	21,037,805			100	%

Basis_of_Presentation_and_Abil1

Basis of Presentation and Ability to Continue as a Going Concern (Details Textual) (Subsequent Event [Member], New Bank [Member], USD $)	1 Months Ended
	Apr. 30, 2014	1-May-14
Subsequent Event [Member] | New Bank [Member]	'	'
Basis Of Presentation [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	$4,000,000
Line of Credit Facility, Periodic Payment	1,800,000	'
Line of Credit Facility, Increase, Accrued Interest	$600,000	'

Businesses_Sold_Details_Textua

Businesses Sold (Details Textual) (USD $)	3 Months Ended		1 Months Ended	0 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Dec. 23, 2013	Nov. 07, 2013
			Gamma Medical Probe [Member]	Lead Paint detector [Member]
Businesses Sold [Line Items]	'	'	'	'
Proceeds from Divestiture of Businesses	'	'	$3,500,000	$1,200,000
Proceeds from Customers	'	'	'	500,000
Repayments of Bank Debt	'	'	2,750,000	1,175,000
Escrow Deposit	'	'	250,000	'
Gain (Loss) on Disposition of Business	1,200,000	'	'	'
Assets Held-for-sale, at Carrying Value, Total	'	2,900,000	'	'
Customer Deposits, Noncurrent	'	$100,000	'	'

Formation_of컞Technologie1

Formation of Xcede Technologies, Inc. Joint Venture (Details Textual) (USD $)	0 Months Ended
	Oct. 02, 2013	Mar. 31, 2014
Schedule of Equity Method Investments [Line Items]	'	'
Proceeds from Convertible Debt	$400,000	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Capital Stock Financing Discount Percentage	20.00%	'
Common Stock Valuation	5,000,000	'
Equity Method Investment, Ownership Percentage	'	90.00%
Common Stock, Conversion Features	'at any time prior to a capital stock financing the note holders can convert at their option into common stock based on a $5 million valuation.	'
Additional Capital Raised	'	$250,000

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Sep. 30, 2013
Inventory Current [Line Items]	'	'
Raw Materials	$1,741,628	$2,132,962
Work-in-Process	975,194	703,873
Finished Goods	262,728	303,409
Inventory, Net, Total	$2,979,550	$3,140,244

Intangible_Assets_Details

Intangible Assets (Details) (USD $)

Mar. 31, 2014

Sep. 30, 2013

Mar. 31, 2013

Mar. 31, 2014

Sep. 30, 2013

Mar. 31, 2014

Sep. 30, 2013

Mar. 31, 2014

Sep. 30, 2013

Mar. 31, 2014

Sep. 30, 2013

Mar. 31, 2014

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2014

Sep. 30, 2013

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Know How [Member]

Know How [Member]

Trade Names [Member]

Trade Names [Member]

Trade Names [Member]

Biomedical Technologies [Member]

Biomedical Technologies [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful Life (years)

'

'

'

'

'

'5 years

'5 years

'15 years

'15 years

'15 years

'15 years

'

'

'15 years

'5 years

'5 years

Gross Amount

$2,004,957

$6,505,440

'

$888,318

$5,145,638

'

'

'

'

$512,000

$512,000

$344,639

$547,802

'

$260,000

$300,000

Accumulated Amortization

683,396

3,020,857

'

375,380

2,645,715

'

'

'

'

196,349

179,283

0

75,856

'

111,667

120,003

Net

$1,321,561

$3,484,583

$3,776,038

$512,938

$2,499,923

'

'

'

'

$315,651

$332,717

$344,639

$471,946

'

$148,333

$179,997

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]	'
2014 (6 months)	$87,043
2015	174,085
2016	172,418
2017	114,085
2018	114,085
Thereafter	315,206
Total	976,922
Acquired Customer Base [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
2014 (6 months)	39,976
2015	79,952
2016	79,952
2017	79,952
2018	79,952
Thereafter	153,154
Total	512,938
Know How [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
2014 (6 months)	17,067
2015	34,133
2016	34,133
2017	34,133
2018	34,133
Thereafter	162,052
Total	315,651
Biomedical Technologies [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
2014 (6 months)	30,000
2015	60,000
2016	58,333
2017	0
2018	0
Thereafter	0
Total	$148,333

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization of Intangible Assets	$43,667	$143,506	$88,555	$324,774

Earnings_Loss_Per_Common_Share2

Earnings (Loss) Per Common Share (Details)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Weighted average shares outstanding	'	'	'	'
Basic	15,102,023	14,770,943	15,061,890	14,721,733
Effect of dilutive securities	'	'	'	'
Dilutive Average Shares Outstanding	15,285,232	14,770,943	15,216,915	14,721,733
Stock Option [Member]	'	'	'	'
Effect of dilutive securities	'	'	'	'
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	0	0	0	0
Restricted Stock [Member]	'	'	'	'
Effect of dilutive securities	'	'	'	'
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	183,209	0	155,025	0

Earnings_Loss_Per_Common_Share3

Earnings (Loss) Per Common Share (Details Textual)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Earnings Loss Per Common Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	630,532	710,532	630,532	710,532

Stock_Based_Compensation_Detai

Stock Based Compensation (Details) (USD $)	6 Months Ended
	Mar. 31, 2014	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Balance,Options Outstanding	630,532	710,532	794,483	'
Outstanding and exercisable,Options	630,532	710,532	794,483	'
Granted,Options Outstanding	0	'	0	'
Exercised,Options Outstanding	0	'	0	'
Cancelled, Options Outstanding	0	'	-83,951	'
Balance,Options Outstanding	630,532	630,532	710,532	794,483
Outstanding and exercisable,Options	630,532	630,532	710,532	794,483
Balance,Weighted Average Exercise Price per Share	$3.33	$3.30	$3.34	'
Outstanding and exercisable,Weighted Average Exercise Price per Share	$3.33	$3.30	$3.34	'
Granted,Weighted Average Exercise Price per Share	$0	'	$0	'
Exercised,Weighted Average Exercise Price per Share	$0	'	$0	'
Cancelled,Weighted Average Exercise Price per Share	$0	'	$3.69	'
Balance,Weighted Average Exercise Price per Share	$3.33	$3.33	$3.30	$3.34
Outstanding and exercisable,Weighted Average Exercise Price per Share	$3.33	$3.33	$3.30	$3.34
Balance,Weighted Average Remain Contractual Term (In Years)	'6 months 22 days	'1 year 22 days	'1 year 4 months 28 days	'1 year 9 months
Outstanding and exercisable options,Weighted Average Remain Contractual Term (In Years)	'6 months 22 days	'1 year 22 days	'1 year 4 months 28 days	'1 year 9 months

Stock_Based_Compensation_Detai1

Stock Based Compensation (Details 1) (USD $)	6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares Nonvested, Beginning Balance	423,168	127,834
Shares, Granted	0	104,000
Shares, Vested	-50,000	-53,000
Shares, Cancelled	0	-20,000
Shares, Nonvested, Ending Balance	373,168	158,834
Weighted-Average Grant-Date Fair Value, Nonvested, Beginning Balance	$0.74	$1.92
Weighted-Average Grant-Date Fair Value, Granted	$0	$1.03
Weighted-Average Grant-Date Fair Value, Vested	$1.05	$1.21
Weighted-Average Grant-Date Fair Value, Cancelled	$0	$4.02
Weighted-Average Grant-Date Fair Value, Nonvested, Ending Balance	$0.70	$1.31

Stock_Based_Compensation_Detai2

Stock Based Compensation (Details 2) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Stock Based Compensation [Line Items]	'	'	'	'
Stock Compensation Expense	$119,579	$136,612	$239,225	$210,128
Stock Grants [Member]	'	'	'	'
Stock Based Compensation [Line Items]	'	'	'	'
Stock Compensation Expense	50,627	80,091	101,253	132,552
Restricted Stock Grants [Member]	'	'	'	'
Stock Based Compensation [Line Items]	'	'	'	'
Stock Compensation Expense	68,351	53,076	136,702	65,694
Option Grants [Member]	'	'	'	'
Stock Based Compensation [Line Items]	'	'	'	'
Stock Compensation Expense	0	2,454	0	9,813
Employee Stock Purchase Plan [Member]	'	'	'	'
Stock Based Compensation [Line Items]	'	'	'	'
Stock Compensation Expense	$601	$991	$1,270	$2,069

Stock_Based_Compensation_Detai3

Stock Based Compensation (Details Textual) (USD $)	Mar. 31, 2014
Stock Based Compensation [Line Items]	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$103,000

Segment_Customer_and_Geographi2

Segment, Customer and Geographical Reporting (Details) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	$10,406,458	$10,484,530	$21,117,986	$21,037,805	'
Gross Profit	4,358,887	4,641,513	8,809,415	9,147,767	'
Impairment of goodwill	0	6,763,072	0	6,763,072	'
Operating Income (Loss)	467,227	-7,248,014	2,081,444	-7,439,301	'
Depreciation and Amortization	268,448	443,717	534,773	870,175	'
Capital expenditures	408,558	-99,889	539,476	215,679	'
Intangibles, Net	1,321,561	3,776,038	1,321,561	3,776,038	3,484,583
Goodwill	6,272,228	6,135,642	6,272,228	6,135,642	6,240,983
Total Assets	24,833,473	28,278,468	24,833,473	28,278,468	26,677,226
Contract Research [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	5,614,060	5,487,850	11,454,502	10,398,690	'
Gross Profit	2,441,719	2,647,870	4,971,257	4,861,923	'
Impairment of goodwill	0	0	0	0	'
Operating Income (Loss)	241,938	232,015	590,332	231,409	'
Depreciation and Amortization	69,949	79,637	139,496	142,419	'
Capital expenditures	12,028	-187,425	12,028	-1,095	'
Intangibles, Net	315,651	349,786	315,651	349,786	'
Goodwill	4,938,625	4,938,625	4,938,625	4,938,625	'
Total Assets	10,230,207	13,332,151	10,230,207	13,332,151	'
Optics [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	4,788,669	3,931,766	8,887,177	8,183,706	'
Gross Profit	1,919,261	1,481,948	3,516,521	3,061,891	'
Impairment of goodwill	0	0	0	0	'
Operating Income (Loss)	522,112	2,336	920,544	388,012	'
Depreciation and Amortization	183,499	184,696	361,607	370,324	'
Capital expenditures	396,530	87,536	527,448	209,682	'
Intangibles, Net	857,579	866,488	857,579	866,488	'
Goodwill	1,333,603	1,197,017	1,333,603	1,197,017	'
Total Assets	13,815,832	9,748,703	13,815,832	9,748,703	'
Instruments [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	0	1,014,320	772,578	2,298,358	'
Gross Profit	-5,822	461,101	317,908	1,066,902	'
Impairment of goodwill	0	6,763,072	0	6,763,072	'
Operating Income (Loss)	-75,585	-7,270,801	966,178	-7,726,495	'
Depreciation and Amortization	0	164,384	2,003	327,432	'
Capital expenditures	0	0	0	7,092	'
Intangibles, Net	0	2,349,767	0	2,349,767	'
Goodwill	0	0	0	0	'
Total Assets	455,096	4,862,956	455,096	4,862,956	'
Biomedical [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	3,729	50,594	3,729	157,051	'
Gross Profit	3,729	50,594	3,729	157,051	'
Impairment of goodwill	0	0	0	0	'
Operating Income (Loss)	-221,238	-211,564	-395,610	-332,227	'
Depreciation and Amortization	15,000	15,000	31,667	30,000	'
Capital expenditures	0	0	0	0	'
Intangibles, Net	148,331	209,997	148,331	209,997	'
Goodwill	0	0	0	0	'
Total Assets	$332,338	$334,658	$332,338	$334,658	'

Segment_Customer_and_Geographi3

Segment, Customer and Geographical Reporting (Details 1) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue	$10,406,458	$10,484,530	$21,117,986	$21,037,805
% of Total	100.00%	100.00%	100.00%	100.00%
United State [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue	8,621,552	8,572,033	17,529,282	17,066,521
% of Total	83.00%	82.00%	83.00%	81.00%
Europe [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue	844,963	847,662	1,674,400	1,736,003
% of Total	8.00%	8.00%	8.00%	8.00%
Other Credit Derivatives [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue	$939,943	$1,064,835	$1,914,304	$2,235,281
% of Total	9.00%	10.00%	9.00%	11.00%

Segment_Customer_and_Geographi4

Segment, Customer and Geographical Reporting (Details Textual)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
Three Customer [Member] | Sales Revenue, Net [Member]	'	'	'	'
Segment Reporting [Line Items]	'	'	'	'
Concentration Risk, Percentage	'	30.00%	24.00%	32.00%
Optics [Member]	'	'	'	'
Segment Reporting [Line Items]	'	'	'	'
Concentration Risk, Percentage	'	'	10.00%	'
Biomedical Technologies [Member] | Customer One [Member]	'	'	'	'
Segment Reporting [Line Items]	'	'	'	'
Concentration Risk, Percentage	'	'	100.00%	100.00%
Customer Concentration Risk [Member]	'	'	'	'
Segment Reporting [Line Items]	'	'	'	'
Concentration Risk, Percentage	69.00%	64.00%	67.00%	63.00%

Income_Taxes_Details_Textual

Income Taxes (Details Textual)	3 Months Ended		6 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Sep. 30, 2013
Income Tax [Line Items]	'	'	'	'
Effective Income Tax Rate Reconciliation, Percent, Total	1.80%	2.50%	-2.40%	2.30%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	'	'	34.00%	'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	Mar. 31, 2014	Apr. 30, 2014	1-May-14	1-May-14
		MiddleSex Savings Bank [Member]	MiddleSex Savings Bank [Member]	Massachusetts Capital Resource [Member]
Subsequent Event [Line Items]	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	'	$4,000,000	'
Line of Credit Facility, Periodic Payment	'	1,800,000	'	'
Line of Credit Facility, Increase, Accrued Interest	'	600,000	'	'
Line of Credit Facility, Amount Outstanding	'	'	$2,400,000	$3,000,000
Debt Instrument, Interest Rate, Effective Percentage	3.25%	'	'	'